Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Cancer Discov. 2020 Jun 22;10(9):1352–1373. doi: 10.1158/2159-8290.CD-19-1228

Figure 5. Pharmacological inhibition of PHGDH decreases serine synthesis and cell proliferation.

Figure 5.

(A) Fractional labeling of intracellular U-13C-glucose-derived m+3 serine from aggressive TNBC BrM cells treated with DMSO or 1 μM of the PHGDH inhibitor PH-719 in Plasma, CSF, or -Ser/-Gly media.

(B) Fractional labeling of intracellular U-13C-glucose-derived m+3 serine from aggressive TNBC BrM cells treated with DMSO or 1 μM of the PHGDH inhibitor PH-755 in Plasma, CSF, or -Ser/-Gly media.

(C) Proliferative capacity of aggressive TNBC BrM cells treated with DMSO or PH719 (1 μM) in Plasma, CSF, or -Ser/Gly media.

(D) Anchorage independent growth of 5B1 brain-trophic melanoma cells grown in plasma, CSF, or -Ser/-Gly media treated with DMSO (control; red bars) or 1 μM PH-755 (blue bars) for 5 days.

(E) Anchorage independent proliferation of patient-derived Short-Term Culture 12-273 Melanoma Brain Metastasis (STC 12-273BM) melanoma cells grown in plasma, CSF, or -Ser/-Gly media treated with DMSO (control; red bars) or 1 μM PH-755 (blue bars) for 5 days.

(F) Proliferation capacity of patient-derived Clear Cell Renal Cell Carcinoma (CCRCC) Brain Metastasis cells grown in plasma, CSF, or -Ser/-Gly media treated with DMSO (control; red bars) or 1 μM PH-719 (blue bars) for 5 days.